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6/j.bEx vivo expansion of cord blood (CB) hematopoietic stem cells and cotransplantation of 2 CB units (CBUs)
could enhance the applicability of CB transplantation in adult patients.We report an immunodeficient mouse
model for cotransplantation of ex vivo expanded and unexpanded human CB, showing enhanced CB engraft-
ment and provide proof of concept for this transplantation strategy as a means of overcoming the limiting cell
numbers in each CBU. CBUs were expanded in serum-free medium supplemented with stem cell factor, Flt-3
ligand, thrombopoietin, and insulin growth factor binding protein-2 together with mesenchymal stromal cell
coculture. Unexpanded and expanded CB cells were cotransplanted by tail vein injection into 45 sublethally
irradiated nonobese diabetic SCID-IL2g2/2 (NSG) mice. Submandibular bleeding was performed monthly,
and mice were sacrificed 4 months after transplantation to analyze for human hematopoietic engraftment.
Expansion of non-CD341 selected CB cells yielded 40-fold expansion of CD341 cells and 3.1-fold expansion
of hematopoietic stem cells based on limiting dilution analysis of NSG engraftment. Mice receiving expanded
grafts exhibited 4.30% human cell repopulation, compared with 0.92% in mice receiving only unexpanded
grafts at equivalent starting cell doses, even though the unexpanded graft predominated in long-term hema-
topoiesis (P5.07). Ex vivo expanded graftswith lower initiating cell doses also showedequivalent engraftment
to unexpanded grafts with higher cell dose (8.0% versus 7.9%; P 5 .93). In conclusion, ex vivo expansion
resulted in enhanced CB engraftment despite eventual rejection by the unexpanded CBU.
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More than 22,000 hematopoietic stem cell (HSC)
transplantations are performed annually worldwide
for patients with leukemia, bone marrow failure, and
other disorders of the blood and immune system [1].
In the last 2 decades, cord blood (CB) has been increas-
ingly used as an alternative to the more common HSC
sources (ie, bone marrow and peripheral blood). This
is due to its many advantages, including permissiveness
to HLA mismatching, lower risk of graft-versus-host
disease (GVHD), ready availability, and the superior
proliferative capacity of CB HSCs compared with
marrow or peripheral blood [2]. However, CB trans-
plantation is generally limited to children and smaller
adults, given that the number of cells in each CB unit
(CBU) is insufficient for most adults.
Double CB transplantation (DCBT) involving the
cotransplantation of 2 CBUs could partially overcome
the barrier of insufficient cell dose. Coinfusion of 2
Table 1. Experimental Design for NSG Mice Transplantation
Group
Total Initial Cell
Dose,  106 Cells
Cells Used for Each CBU
CB-A,  106 Cells CB-B,  106 Cells
1 2 2 -
2 2 - 2
3 2 1 1
4 2 0.4 1.6
5 2 1.6 0.4
6 1 0.5 0.5*
7 1 0.5* 0.5
8 2 1 1*
9 2 1* 1
*Represents the number of input CB cells prior to expansion.
Biol Blood Marrow Transplant 18:674-682, 2012 675Expanded Double Cord Blood Transplantation in MiceCBUs does not always provide sufficient cells for en-
graftment, however [3]. To surmount this problem,
a modified version of DCBT involving cotransplanta-
tion of an ex vivo expanded CBU and an unexpanded
CBU was postulated to be beneficial. Ex vivo expan-
sion of 1 of the 2 CBUs could potentially enhance en-
graftment by increasing the number of HSCs and
hematopoietic progenitor cells, and the unexpanded
unit provides a ready source of HSCs, should the ex-
vivo expansion fail. To date, many preclinical studies
have been performed, but none has truly mimicked
the conditions under which these DCBT ex vivo ex-
pansion CB clinical trials are being conducted [4-6].
Recently, a combination of cytokines, including
insulin growth factor binding protein-2 (IGFBP2)
and angiopoietin-like 3, was shown to result in a
20-fold net expansion of repopulating human CB
HSCs with CD1331 selected CB cells [7]. Mesenchy-
mal coculture has also been shown to augment ex vivo
CB expansion [8,9].
In the present study, we used a combination of
mesenchymal coculture and IGFBP2 supplementation
in our unselected CB expansion protocol, with co-
transplantation of expanded CB cells into NOD/
SCID-IL2g2/2 (NSG) mice together with an unex-
panded CBU in a DCBT setting. Engraftment results
show that DCBT with 1 expanded CBU and 1 unex-
panded CBU enhanced human hematopoietic engraft-
ment in NSGmice compared with CBT with single or
double unexpanded CBU.
MATERIALS AND METHODS
Preparation of Cells
Fresh umbilical CB was obtained from Singapore
Cord Blood Bank. The use of CB was reviewed and ap-
proved by the Singapore Cord Blood Bank Research
Advisory Ethics Committee, as well as the Institutional
Review Boards of National University of Singapore
and Singapore General Hospital. Mononuclear cells
(MNCs) were isolated from fresh CBUs by Ficoll-
Histopaque-1077 (Sigma-Aldrich, St Louis, MO)
density gradient centrifugation. No phenotypic cell
selection process was performed for the CB cells.HuES9.E1, a human embryonic stem cell-derived
mesenchymal stem cell (ESMSC) cell line, was main-
tained on gelatin-coated tissue culture plate surface
in DMEM as described previously [10].
CB-MNC Culture with or without Addition of
IGFBP2
For this experiment, 4  105cells/mL of freshly
thawed CB MNCs were cocultured with ESMSCs in
StemSpan serum-free medium (Stemcell Technolo-
gies, Vancouver, Canada) supplemented with 100 ng/
mL of stem cell factor (SCF), 50 ng/mL of Flt-3 ligand
(Flt-3L), and 100 ng/mL of thrombopoietin (TPO)
(all from PeproTech, Rocky Hills, NJ), with or with-
out 20 ng/mL of IGFBP2 (R&D Systems, Minneapo-
lis, MN). One day before seeding of CB cells, ESMSCs
were seeded at a confluent density of 4 104 cells/cm2.
After 11 days of culture, the expansion folds for viable
total nucleated cells (TNCs) and CD341382901 cells
(ie, HSCs) were measured by flow cytometry.
Ex Vivo Expansion of CB Cells for NOD/SCID-
IL2g2/2 Mice Transplantation
WhenESMSCs reached 90% to 100% confluence,
CBMNCs were cocultured with ESMSCs at a density
of 8  105 cells/mL using StemSpan medium supple-
mented with the aforementioned cytokines. On day
7, the medium volume was topped up by adding an
equivalent volume (as on day 0 of coculture) of fresh
StemSpan medium supplemented with cytokines.
Cells were cultured at 37C in 5% CO2 and normal
O2 and harvested on day 11.
NSG Mice Transplantation
NSG mice were purchased from Jackson Labora-
tory (Bar Harbor, ME) via the SingHealth Experimen-
tal Medicine Centre and were maintained in the
Duke–National University of Singapore vivarium. All
animal experiments were conducted with the approval
of SingHealth Institutional Animal Care and Use
Committee. Unexpanded or expanded CB cells were
injected i.v. via the tail vein into sublethally irradiated
(240 cGy) 9- to 12-week old NSG mice. Two CBUs
(designated CB-A and CB-B) were used. Cotransplan-
tation with 1 ex vivo expanded CBU and 1 unexpanded
CBU was defined as ‘‘transplanted with expanded
unit,’’ and transplantation with either 1 single unex-
pandedCBUor double unexpandedCBUswas defined
as ‘‘transplanted with unexpanded unit.’’ A total of 45
NSG mice were divided into 9 groups (Table 1). The
mice weremaintained for 4months, with submandibu-
lar bleeding for blood assays performed each month.
Harvesting of Bone Marrow and Spleen
At the end of the fourthmonth posttransplantation,
themicewere sacrificed in aCO2 chamber. Femurs and
tibias were harvested and immediately placed into cold
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Island, NY). Joint ends were cut, and bone marrowwas
flushed out with 10 mL of 2% FBS-RPMI. Then,
spleens were harvested and immediately placed into
0.5 mL of Dulbecco’s phosphate-buffered saline
(Invitrogen) over ice. To harvest HSCs, the harvested
spleens were mechanically sheared through a 40-mm
cell strainer (BD Falcon; BD Biosciences, San Jose,
CA). Both the bone marrow and spleen cell suspension
were washed, after which contaminated red blood cells
were lysed by ammonium chloride-based buffer before
flow cytometry analysis.
Flow Cytometry
All data were acquired using a Cytomic FC500
Flow Cytometer (Beckman Coulter, Marseille,
France), and 10,000 events per sample were collected.
Acquired data were subsequently analyzed with CXP
analysis software (Beckman Coulter). To analyze
ex vivo expansion of CB cells, the cells were stained
for viability, multipotential HSCs, T cells, B cells, reg-
ulatory T cells, na€ıve T cells, and effector T cells. He-
matopoietic cell viability was identified by staining
with CD45-PC7, Annexin V-FITC, and 7-AAD (all
from Beckman Coulter). Multipotential HSCs were
identified by staining with CD45-PC7, CD34-PE,
CD38-APC, and CD90-FITC. B cells, T cells, and
regulatory T cells were identified by staining with
CD45-PC7, CD3-ECD, CD19-PE, CD4-FITC,
CD25-APC, and FoxP3-PE antibodies (all from BD
Biosciences except CD3-ECD and CD19-PE, from
Miltenyi Biotec, Bergisch Gladbach, Germany). Naive
T cells and effector/effector memory T cells were
identified by staining with CD45-FITC, CD3-PE,
CD4-Percp Cy5.5, CD8-ECD, CCR7-PC7, and
CD45RO-APC antibodies (all from BD Biosciences
except CD8-ECD, from Miltenyi Biotec).
To analyze bone marrow and spleen HSCs, the
harvested bone marrow and spleen cells were stained
phenotypically for myeloid and lymphoid lineage.
For myeloid lineage analysis, the cells were stained us-
ing human CD45-APC, CD71-PE, CD15-FITC,
CD66-FITC (all from Miltenyi Biotec) as well as
mouse CD45-PE (BD Biosciences) and mouse CD45
FITC (Miltenyi Biotec). For common myeloid and
lymphoid lineage analysis, the cells were stained using
human CD45-APC, CD34-PE, CD19-FITC, CD20-
FITC (all from Miltenyi Biotec) and CD3-ECD (BD
Pharmingen), as well as mouse CD45-PE and mouse
CD45 FITC (Miltenyi Biotec).
DNA Extraction and Chimerism Studies
Chimerismof eachmousewas determinedby a vari-
able number tandem repeat (VNTR) assay. Genomic
DNA from mouse bone marrow and spleen were ex-
tracted using the QIAamp DNA Mini Kit (Qiagen,
Germantown, MD). PCR amplification of human-specific locus D1S80 [11] was performed using primers
50-GAAACTGGCCTCCAAACACTGCCCGCCG30
and 50-GTCTTGTTGGAGATGCACGTGCCCC
TTGC-3. PCR was performed using DyNAzyme
EXT DNA polymerase (Finnzymes, Espoo, Finland)
under the following conditions. DNA was first dena-
tured at 95C for 2 minutes, then amplified for 5 cycles
of 95C for 30 seconds and 65C annealing for 30 sec-
onds, followed by 1 cycle of elongation at 72C for 45
seconds, and final extension at 72C for 10 minutes.
Genomic DNA samples from humanCB (positive con-
trol) and bone marrow cells of nontransplanted mice
(negative controls) were processed in parallel. Ampli-
fied PCR products were electrophoresed in 2.6%
agarose gels, stained with ethidium bromide (Sigma-
Aldrich, St Louis,MO), and visualized underUV light.
IFN-g Intracellular Staining
Peripheral blood (100-150 mL) was collected from
NSGmice transplantedwith doubleCBUs by subman-
dibular bleeding on day 45 posttransplantation. Col-
lected peripheral blood from each group (Table 1)
was pooled, and 6  105 peripheral blood cells were
stimulated with 1.5 105CD32 selectedmononuclear
cells from either donor unit for 5 hours in 3 mL of
HEPES (Invitrogen) supplemented with 10% FBS
(Hyclone Laboratories, Logan, UT) and 35 U/mL of
penicillin/streptomycin (Invitrogen) at 37C in a hu-
midified 5% CO2 incubator. For IFN-g intracellular
staining, 5 mg/mL of brefeldin A (Sigma-Aldrich) was
added after a 1-hour incubation. Unstimulated con-
trols were included as well. The cells were stained
with live/dead fixable violet stain–ECD (Invitrogen)
and CD3-PE, CD4-Percp Cy5.5, CD8-ECD,
CCR7-PC7, and CD45RO-APC surface antibodies
(all from BD Biosciences) for 20 minutes at 4C. After
fixation/permeabilization (Cytofix/Cytoperm; BD
Biosciences), cells were washed and subjected to
IFN-g FITC intracellular staining for 30 minutes.
Statistical Analysis
Results are reported as mean6 standard deviation.
The significance of difference between 2 groups was
determined using the 2-tailed Student t-test. Analysis
of variance was used to determine the significance of
difference among 3 or more groups. A P value\.05
was considered to indicate statistical significance.
Data processing and statistical analysis were performed
with OriginPro 7.5 (OriginPro, Northampton, MA).
RESULTS
IGFBP2 Selectively Expands HSCs in Whole
Cord Blood by 21-Fold in a Mesenchymal
Stromal Coculture System
IGFBP2 did not significantly increase the expan-
sion of viable TNCs (P 5 .08), but it increased
Figure 1. Ex vivo expansion of cord blood units using cytokines. (A)
Viable TNCs and CD341382901 expansion fold of CB cells in the pres-
ence of IGFBP2. Cord blood cells were inoculated at the density of 4 
105cells/mL and cocultured withmesenchymal stromal cells for a total of
11 days. Basal culture medium for control groups were cultured in the
presence of 50 ng/mL of SCF, Flt-3 50 ng/mL and 100 ng/mLTPO. There
is no significant difference for the expansion of viable TNCs between
control and IGFBP2 group (P 5 .08). With the addition of 20 ng/mL of
IGFBP2, there is a 21-fold CD341382901 (ie, HSCs) expansion fold
compared to control (P 5 .001) (n 5 2). (B) Expansion profile of the 2
cord blood units used for NSG mice transplantation. Cord blood cells
cocultured with mesenchymal stromal cells in the presence of 100 ng/
mL of SCF, 50 ng/mL of Flt-3, 100 ng/mL of TPO and 20 ng/mL of IGFBP2
for 11 days. There is an overall 3.2-fold expansion of viable TNC, 30-fold
expansion of CD341 cells, and eight fold expansion of
CD341CD382CD901 cells. CD191 (B cells) and CD31 (T cells)
were reduced by three to five fold with this expansion protocol. Results
are mean 6 SD of expansion fold from a single experiment with tripli-
cate assay (n 5 2).
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fold (P\.001) (Figure 1A). To assess the reproducibil-
ity of the IGFBP2 effect, we expanded 2 CBUs (CB-A
and CB-B) with IGFBP2 supplementation. Expansion
of both CBUs was similar, with a 3.2-fold expansion of
viable TNCs, a 30-fold expansion of CD341 cells, an
eight fold expansion of CD341CD382CD901 cells,
and a two- to fivefold reduction in CD191 and
CD31 cells (Figure 1B). Therefore, ex vivo culture ofCB MNCs with IGFBP2 supplementation and MSC
coculture selectively expanded HSCs.
SuperiorHumanHematopoietic Engraftment in
Mice Receiving Expanded CB Cells
We performed an NSG repopulation assay to test
whether the ex vivo expandedCB cells would lead to in-
creased and sustained hematopoietic engraftment
compared with unexpanded CB cells. The percentage
of human CD45 cell repopulation was compared in
the mice receiving unexpanded 2  106 CB cells and
those receiving expanded 2  106 CB cells. At the
same initial starting dose, transplantation of an ex-
panded CBU resulted in a higher percentage of
CD45 cell repopulation, although the differences in
mean values were not statistically significant for pe-
ripheral blood (4.30% 6 2.72% versus 0.92% 6
1.14%; P5 .07), bonemarrow (14.67%6 19.79% ver-
sus 1.61% 6 2.48%; P 5 .23), and spleen (59.27% 6
19.76% versus 27.05% 6 29.00%; P 5 .16)
(Figure 2A). However, at a starting dose of 1  106
for expanded CBUs and 2  106 for unexpanded
CBUs, the percentages of CD45 cell repopulation
were equivalent for peripheral blood (8.0% 6 13.2%
versus 7.9% 6 10.0%; P 5 .93), bone marrow (4.5%
6 7.0% versus 10.5% 6 14.3%; P 5 .30), and spleen
(37.5% 6 32.9% versus 39.1% 6 23.9%; P 5 .90)
(Figure 2B). Based on limiting dilution analysis of
NSG mice engraftment results (with a positive result
defined as .1% human HSC engraftment), mice un-
dergoing transplantation with 1  106 of expanded
CB cells had a similar percentage ofHSCs (competitive
repopulation unit [CRU] 5 1/1.76e6) compared with
those receiving 2  106 unexpanded CB cells (CRU
5 1/1.68e6). There was a 3.1-fold expansion of HSCs
during the ex vivo expansion when the 3.2-fold expan-
sion of TNCs was taken into account (Figure 2C).
Comparable Multilineage Profile between
Unexpanded and Expanded CBUs
Multilineage engraftment was compared in NSG
mice receiving unexpanded CB cells and those receiv-
ing expanded CB cells at 4 months posttransplantation
(Figures 2D and 3). There was no significant difference
in the mean percentage of repopulation for the human
myeloid lineage (CD34, CD71, and CD66b/CD15)
and lymphoid lineage (CD19/CD20 and CD3) be-
tween the mice that received unexpanded and ex-
panded CB cells (CD71, P 5 .06; CD6615, P 5 .23;
CD34, P 5 .09; CD1920, P 5 .13; CD3, P 5 .78).
Unexpanded CBU Predominating in Final
Donor Chimerism Due to the Immune Reaction
between the 2 Donor CBUs
DNA extraction was performed on the collected
bone marrow and spleen for chimerism studies. All of
Figure 2. Human CD45 repopulation in the peripheral blood, bone marrow, and spleen of NSG mice. (A) Mice that underwent a transplantation of 2
106 unexpanded versus a transplantation of 2 106 expandedCB cells (cell dose 1:1). (B) Mice that underwent a transplantation of 2 106 unexpanded
versus a transplantation of 1106 expanded CB cells (cell dose 2:1). Each symbol represents engraftment of a single mouse that underwent transplan-
tation assayed at 4months after transplantation. Results are expressed asmean6 SDof percentage of engraftment from a single experiment. (C) Limiting
dilution analysis of double cord blood transplantation performed in NSGmice. Negative engraftment was defined by less than 1% human CD45 engraft-
ment in the bonemarrow. (D)Multilineage engraftment inNSGmice that underwent a transplantation of unexpanded or expanded cord blood cells. Each
symbol represents engraftment of a single mouse that underwent transplantation assayed at 4 months after transplantation. Some mice had 0% donor
repopulation, and these are not plotted. Results are expressed as mean 6 SD of percentage of engraftment from a single experiment (n 5 1).
678 Biol Blood Marrow Transplant 18:674-682, 2012L. M. Ong et al.the mice that underwent DCBT had single CBU dom-
ination. OnVNTR analysis, the unexpandedCBUwas
shown to dominate over the expanded CBU at 4
months after transplantation. We also investigated
the potential role of an immune reaction in mediating
final CBU dominance after DCBT in mice. We
performed a multiparameter flow cytometry assay
designed to detect whether IFN-g–secreting T cells
that developed in the recipient mice after DCBT
were capable of specific recognition of cells derived
from either CBU. After a 5-hour stimulation of periph-
eral blood with CD3-selected mononuclear cells from
either donor CBU, a significant CD81CD45RO1/2
CCR72 IFN-g–secreting cell population, effector
CD81 T cells, was detected in the mice stimulated
with nonengrafted CBUs (1.5% 6 1.1%), whereas
IFN-g response was undetectable in the group stimu-
lated with engrafted CBUs (0%) (Figure 4A). Fur-
thermore, FACs analysis of CB cells before
cotransplantation showed that 70% of unexpandedgrafts consisted of CD31 cells, compared with only
4% of expanded grafts (Figure 4B). These data provide
a possible explanation of why the unexpanded CBU
achieves eventual unit dominance in recipient mice.
Furthermore, greater human cell engraftment was
seen in the mouse peripheral blood at 1 month post-
transplantation in themice receiving expandedCBcells
compared with those receiving unexpanded CB cells
(21.4% 6 3.8% versus 10.9% 6 4.3%; P 5 .08)
(Figure 4C), suggesting that the expanded cells con-
tribute to early stages of engraftment.Possible GVHD-Related Deaths Due to High
Proportion of CD31 T Cells in the Unexpanded
CB Unit
In themouse experiment described earlier, 14 of the
34 mice died during the first 2 months after transplan-
tation. Before death, those mice exhibited hair loss,
weight loss, lack of vigor, and a hunchback appearance.
Figure 3. Representative fluorescence-activated cell sorting plots of bone marrow cells. Flow cytometric data from 3 representative mice. Lane 1,
control; lane 2, mouse injected with unexpanded 1  106 cells CB-A and unexpanded 1  106 cells CB-B; lane 3, mouse injected with unexpanded
1  106 cells CB-A and expanded 1  106 cells CB-B at 4 months after transplantation. Mice with best engraftment were chosen for unexpanded
and expanded group. Percentages of cells in each quadrant are listed.
Biol Blood Marrow Transplant 18:674-682, 2012 679Expanded Double Cord Blood Transplantation in MiceInterestingly, the survival rate was 80% in the mice re-
ceiving expanded CB cells, compared with 50% from
mice receiving unexpanded CB cells (Figure 5A). T
cell population analysis results before and after ex vivo
expansion from another independent mouse experi-
ment found 20-fold, 37-fold, and six fold increases
in CD31 T cells, CD31CD41 helper T cells, andCD31CD81 cytotoxic T cells, respectively, whereas
a three fold decrease in CD41CD251Foxp31 regula-
tory T cells in the unexpanded CBUs compared with
the expanded CBUs (Figure 5B). In the helper T cell
population, there were 73.5% na€ıve T cells in the unex-
panded CBUs versus 7.5% in the expanded CBUs and
25% effector T cells in the unexpanded CBUs versus
Figure 4. Immunoreaction between dual CBUs and proportion of
CD31T cells within expanded and unexpanded units. (A)Mouse periph-
eral blood collected 45 days after transplantation shows presence of
CD81CD45RO1/2CCR72 IFN-g–secreting cells that are reactive
against CD32 selected cells from the nonengrafted CBU and the en-
grafted CBU. IFN-g–secreting CD81 T cells are also detectable among
8 groups of mice establishing single donor dominance (n5 1). (B) CD31
T cell population analysis before and after ex vivo expansion. (C) Human
cell engraftment in NSG mice peripheral blood at 1 month posttrans-
plantation with 2  106 expanded and unexpanded cells.
680 Biol Blood Marrow Transplant 18:674-682, 2012L. M. Ong et al.77.5% in the expanded CBUs (Figure 5C). In the cyto-
toxic T cell population, there were 48% na€ıve T cells in
the unexpanded CBUs versus 2% in the expanded
CBUs and 49% effector T cells in the unexpanded
CBUs versus 95.5% in the expanded CBUs(Figure 5C). When a 3.2-fold ex vivo expansion of
TNCs was taken into account, CB expansion resulted
in six fold lower concentration of CD31 T cells, a 12-
fold lower concentration of CD31CD41 helper T
cells, a two fold lower concentration of CD31CD81
cytotoxic T cells, and a 10-fold higher concentration
of CD41CD251Foxp31 regulatory T cells. The
higher regulatory T cell and lower CD31 cell content
in the expanded cells help explain the higher survival
rate in mice undergoing transplantation with at least
one ex vivo expanded CBU. Of note, despite a higher
proportion of na€ıve T cells in the unexpanded CBUs,
most of these cells (95%-98%) transformed to effector
T cells after infusion (Figure 5D).DISCUSSION
In this study, we found that IGFBP2 enhanced
ex vivo CB expansion in a mesenchymal stromal cocul-
ture system, resulting in a 21-fold increase in HSCs.
Furthermore, in a DCBT model, we found superior
human hematopoietic engraftment in mice receiving
expanded CB cells, although the unexpanded CBU
predominated in final donor chimerism.
Both the cytokines and the mesenchymal stromal
coculture system used in this study likely contributed
to this enhanced human hematopoietic engraftment.
Various cytokines dictate the cellular fates of HSCs,
including self-renewal, differentiation, apoptosis, and
quiescence. Out of the 4 cytokines studied, SCF,
Flt-3L, and TPO are widely used for ex vivo expansion
of CB cells, but IGFBP2 is not. The addition of
IGFBP2 has been shown to expand CB HSCs through
an as-yet-unknown mechanism [7,12]. Fei et al [8] re-
ported that coculture of CB CD341 cells with mesen-
chymal stromal cells could enhance rapid engraftment
of CB cells in NOD/SCID mice [8]. This is consistent
with Schofield’s ‘‘niche hypothesis’’ [13], in which
mesenchymal coculture could simulate the native
bone marrow microenvironment, restoring the origi-
nal interaction between the marrow stroma and the
HSCs [14-18].
In comparisonsof humancell engraftment ratewith
unexpandedCBUs andwith expandedCBUs, all results
reported here are based on the initial cell dose. The ini-
tial cell dose before expansion is a valid basis for com-
parison, being a major determinant of CB selection in
CB trials [19,20]. We found greater mean human cell
repopulation in the group receiving expanded CBUs,
with difference approaching statistical significance
(P 5 .07). This finding was consistent in all 3 tissues
analyzed (peripheral blood, bone marrow, and
spleen). Furthermore, the expanded CBUs provided
a similar engraftment rate despite a lower initial cell
dose, suggesting that this ex vivo expansion protocol
could make CB transplantation a viable option for
Figure 5. Low survival relates to high population of CD31 T cells in the unexpanded unit. (A) Kaplan-Meier survival estimates of the probability of
survival. A total of 24 NSG mice underwent transplantation with 2  106 of double unexpanded units, and 10 NSG mice underwent transplantation
with double CBUs comprising 0.5 106 unexpanded and 1.5 106 expanded cord blood cells. (B and C) Analysis of T cell populations before and after
ex vivo expansion. (D) Analysis of T cell populations of the NSG mice peripheral blood on day 45 posttransplantation.
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insufficient cell dose.
Despite the superior human hematopoietic en-
graftment in mice receiving expanded CB cells, it
was interesting to note that the unexpanded CBU pre-
dominated eventually, as has been reported previously.
In 10 subjects with high-risk acute leukemia, Delaney
et al. [21] performed clinical ex vivo expansion using
immobilized engineered Notch ligand with cytokines
(SCF, Flt3 ligand, TPO, IL-6, and Il-3), followed by
the infusion of one unexpanded CBU and one
Notch-expanded CBU. At 80 days posttransplanta-
tion, they found that the expanded CBU contributed
to the initial myeloid engraftment, but eventual donor
engraftment was 100% from the unexpanded CBU.
Although we did not have sufficient DNA to perform
the first month’s VNTR analysis, the greater human
cell engraftment in peripheral blood in the NSG
mice that received expanded CBUs suggested that
the expanded CBUs, with greater numbers of stem/progenitor cells, can enhance early-stage engraftment.
Nonetheless, given that CB transplantation often re-
sults in delayed engraftment compared with other
HSC sources [22], the rapid engraftment provided by
cotransplantation of expanded CBUs could lead to sig-
nificant reduction in mortality.
The lack of in vivo persistence of the expanded
CBUs might possibly be related to a loss of stem/pro-
genitor cell renewal potential or immune rejection.
We believe that decreased stem/progenitor cell re-
newal potential is not responsible, for 3 reasons. First,
our expansion results show a 21-fold increase in
CD341382901 cells (ie, HSCs) compared with con-
trols. Second, our limiting dilution analysis data show-
ing a 3.1-fold increase in HSCs do not appear to
support the connection. Finally, our single CB trans-
plantation study (unpublished data) found significantly
higher CD34 (stem cell progenitor) repopulation in
NSG mice receiving expanded CBUs compared with
those receiving unexpanded CBUs.
682 Biol Blood Marrow Transplant 18:674-682, 2012L. M. Ong et al.Based on our data, we believe that the mechanism
of single CBU dominance after DCBT involves an im-
mune reaction of a specific CD81 T cell response
against the nonengrafted CBU. This assumption
is consistent with findings reported by Gutman et al
[23], who demonstrated in an in vitro assay that
single-unit dominance resulted from an IFN-g
response by CD81CD45RO1/2CCR72 effector
memoryT cells in the winning unit against the rejected
unit. Yahata et al. [4] reported that when mononuclear
cells (ie, B, T, and NK cells) from 2 CBUs were co-
transplanted with CD341 cells into immunodeficient
NOD/SCID/gcnull mice, engraftment was dominated
by one of the CBUs, whereas when only purified
CD341 cells were transplanted, both CBUs engrafted
as expected. Of note, our expansion findings show
a17.5-fold higher CD31 cell fraction in unexpanded
CBUs than in expandedCBUs. Furthermore, although
the majority of T cells in the unexpanded CBUs before
infusion were na€ıve T cells, 95% to 98% of these trans-
formed to effector T cells after infusion. As such, the
expanded CBU, with a much lower T cell content
(\1%), could be rejected by the unexpanded CBU
through an immune reaction.
To the best of our knowledge, this is the first report
of DCBT in the NSGmouse model using 1 ex vivo ex-
panded CBU and 1 unexpanded CBU, based on an
expansion protocol using the novel cytokine IGFBP2
in a mesenchymal stromal coculture system. We have
shown that ex vivo expansion resulted in greater en-
graftment in the immunodeficient mice, whereas the
unexpanded CBU predominated in long-term hema-
topoiesis, possibly due to immune-mediated rejection
of the expanded CBU by the unexpanded CBU.ACKNOWLEDGMENTS
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